Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by a. I. F. Tannock
Treatment of Hormone-Refractory Prostate Cancer With Docetaxel or Mitoxantrone: Relationships Between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer
Mayo Clinic Proceedings
Medicine
Prostate-Specific Antigen Response to Withdrawal of Megestrol Acetate in a Patient With Hormone-Refractory Prostate Cancer
Mayo Clinic Proceedings
Medicine
Low-Dose Docetaxel in Combination With Dexamethasone for Hormone-Refractory Prostate Cancer
Japanese Journal of Urology
Urology
Mp86-14 Prostate Specific Antigen and Health-Related Quality-Of-Life Outcomes in Uninsured Men With Prostate Cancer
Journal of Urology
Urology
Hormone-Refractory Prostate Cancer
Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer
Cancer
Cancer Research
Oncology
Achieving Treatment Goals for Hormone-Refractory Prostate Cancer With Chemotherapy
Oncologist
Cancer Research
Medicine
Oncology
The Role of Prostate-Specific Antigen in Prostate Cancer Screening
Romanian Review of Laboratory Medicine
Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer
European Urology
Urology
